This clinical trial is focused on studying infertility and involves treatments that support assisted reproduction techniques. The study will use several medications, including choriogonadotropin alfa (also known as FE 999302), nomegestrol acetate combined with estradiol hemihydrate, and progesterone. These medications are used to help with the process of frozen embryo transfer, which is a method where a previously frozen embryo is thawed and transferred to the uterus.
The purpose of the study is to explore whether there are differences in various health aspects of the mother and baby when using different methods of frozen embryo transfer. The study will look at how the presence of the corpus luteum—a temporary structure in the ovaries that produces hormones—affects pregnancies achieved through frozen embryo transfer. Researchers will examine factors such as the function of blood vessels and the placenta, the mother’s heart health, and the growth and development of the fetus.
Participants in the study will receive one of the medications mentioned above, or a placebo, and will be monitored throughout their pregnancy. The study will assess various health indicators, including hormone levels and heart function, to understand the impact of the treatments. The study is expected to continue until 2027, with recruitment starting in 2024.
Spain 